OAC
IKT icon

OMERS Administration Corp’s Inhibikase Therapeutics IKT Stock Holding History

OMERS Administration Corp’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,000
Closed -$123K – 985
2025
Q1 		$123K Buy
56,000
+1,400
+3% +$3.52K ﹤0.01% 970
2024
Q4 		$177K Buy
+54,600
New +$136K ﹤0.01% 883

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OMERS Administration Corp's IKT Position: Q2 2025 in Review

OMERS Administration Corp sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 56,000 shares — an estimated $123K sold.

OMERS Administration Corp first reported a position in IKT in Q4 2024 and held it in 2 quarters. The position peaked at $177K in Q4 2024. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

  • OMERS Administration Corp reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 56,000 Inhibikase Therapeutics shares in Q2 2025, an estimated $123K.
  • OMERS Administration Corp first reported a position in Inhibikase Therapeutics in Q4 2024 and held it in 2 quarters.
  • OMERS Administration Corp's Inhibikase Therapeutics position peaked at $177K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.